Nasdaq GlobeNewswire

XBiotech Announces Presentation of Phase 2 Open Label Extension Study Data Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa

Del

Open Label Extension Results, which Demonstrate Significant Improvements in HS Patients Previously Treated with Placebo, will be Presented at the 7th Conference of the European Hidradenitis Suppurativa Foundation (EHSF)

AUSTIN, Texas, Jan. 19, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that results from an open label extension (OLE) phase of the randomized Phase 2 study evaluating XBiotech's True Human(TM) antibody, MABp1, as a treatment for Hidradenitis Suppurativa (HS), will be presented at the European Hidradenitis Suppurativa Foundation (EHSF) Conference occurring in Rotterdam Netherlands February 7-9th. The oral presentation titled, "An open-label extension study of MABp1 targeting interleukin-1alpha for hidradenitis suppurativa (HS)" will be given by Theodora Kanni, M.D., Ph.D., Attikon University Hospital in Athens Greece, on 8 February 2018 between 1:50 and 2:50pm local time.

The findings being presented come from patients that had received placebo in a previous Phase 2 double-blind, placebo-controlled study. Patients that had originally been allocated to placebo in the Phase 2 study were allowed to receive treatment with the MABp1 antibody therapy in a so called open label extension (OLE) study. Seven of 10 patients that had originally received placebo were treated with MABp1 for 12 weeks. Main endpoints used in the OLE included safety and HiSCR score at the end of the 12 week treatment. At the conclusion of the double-blinded study, only one patient (1 of 10, or 10%) receiving placebo had achieved HiSCR. During the OLE, five patients (5 of 7, or 71.4%) achieved the HiSCR response (p=0.035). There was a total of 24 HS exacerbations during the blinded portion of the study compared to just 1 exacerbation during the OLE phase.

Prof. Evangelos Giamarellos-Bourboulis, M.D., Ph.D., who supervises the Outpatients Department for HS of the 4th Department of Internal Medicine at Attikon University Hospital in Athens, Greece where the study was conducted and also served as the Principal Investigator of the study, commented, "Results of the OLE crossover study provide further compelling evidence of the activity for MABp1 in HS. We will work diligently to expand this work and avail this treatment to patients in need."

Results of the Phase 2 study were recently published in the Journal of Investigative Dermatology, reporting that the study met its primary endpoint and demonstrated a significant improvement in HS patients treated with MABp1 compared to control after 12 weeks of therapy (Response rate of 60% vs 10%, respectively (p=0.035)). The 20 patient double-blind, placebo-controlled study was designed to evaluate the safety and efficacy of MABp1, the Company's True Human antibody targeting interleukin-1 alpha (IL-1alpha), in patients with HS not eligible for anti-TNF therapy. Patients were randomized 1:1 to receive either MABp1 or placebo every 2 weeks for 12 weeks. Patients in the study underwent primary assessment of efficacy using Hidradenitis Suppurativa Clinical Response (HiSCR) scores at 12 weeks, continued by a follow up phase to assess time to relapse after an additional 12 weeks without therapy. Efficacy measures included assessment of HiSCR scores, a validated method for evaluating efficacy in HS patients, as well as quality of life assessment and ultrasonographic evaluation.

About Hidradenitis Suppurativa 
Hidradenitis Suppurativa (HS) is a chronic, inflammatory skin disorder affecting areas rich in apocrine glands. Nodules appear in the affected areas and progressively become swollen with spontaneous rupture and release of pus. This process occurs repeatedly leading to formation of deep sinus tracts and painful dermal abscesses1,2. Therefore, HS is often devastating for patients with significant impact on quality of life3. The Dermatology Life Quality Index (DLQI) for HS is 8.9, being higher than any other skin disorder4. Traditional treatments comprise of antibiotics, antiandrogens and surgery. Prevalence rates for HS have been estimated at up to 4%2.

About True Human(TM) Therapeutic Antibodies
Unlike previous generations of antibody therapies, XBiotech's True Human(TM) antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech's True Human antibodies have the potential to harness the body's natural immunity to fight disease with increased safety, efficacy and tolerability.

About XBiotech
XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human(TM) proprietary technology. XBiotech currently is advancing a robust pipeline of antibody therapies to redefine the standards of care in oncology, inflammatory conditions and infectious diseases. Headquartered in Austin, Texas, XBiotech also is leading the development of innovative biotech manufacturing technologies designed to more rapidly, cost-effectively and flexibly produce new therapies urgently needed by patients worldwide. For more information, visit www.xbiotech.com.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Contact
Ashley Otero
aotero@xbiotech.com
512-386-2930

1 Revuz J. Hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2009; 23: 985-998.

2 Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol. 2009 Apr;60(4):539-61; quiz 562-3. doi: 10.1016/j.jaad.2008.11.911.

3 Vasquez BG, Alikhan A, Weaver, AL, et al. Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota. J Invest Dermatol. 2013 Jan;133(1):97-103. doi: 10.1038/jid.2012.255. Epub 2012 Aug 30.

4 Révuz JE, Canoui-Poitrine F, Wolkenstein P, et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol 2008; 59: 695-701.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: XBiotech, Inc via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Mitratech’s DataStore Helps Financial Services Clients Across the Globe Meet Regulatory Requirements, Reduce Risk and Improve Efficiency12.11.2018 14:01Pressemelding

Major DataStore Update Includes New Reporting Resulting in Greater Visibility and Informed Decision Making AUSTIN, Texas, Nov. 12, 2018 (GLOBE NEWSWIRE) -- To continue to meet growing risk and compliance demands, Mitratech DataStore Enterprise Content Management (ECM) solution now offers advanced reporting capabilities to help financial services reduce risk and improve efficiency across the enterprise. With this new release, Mitratech customers and partners can leverage advanced reporting capabilities that include: Inventory management Workflow management Audit management Performance management “DataStore continues to expand globally. As the only ECM solution dedicated to financial services, we continue to develop our product to meet the unique needs of our clients,” said Jason Cropper, Mitratech Global Head of Product Marketing - GRC. “Compliance and efficiency are pretty much top of mind across the board, and with the enhanced reporting capabilities this release provides, our clients

Starry Leverages Quantenna’s 8x8 MIMO Capabilities to Bring Ultrafast 5G Fixed Wireless Access to Consumers12.11.2018 14:00Pressemelding

SAN JOSE, Calif., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Quantenna Communications, Inc. (NASDAQ : QTNA) and Starry are joining forces to deliver pioneering gigabit Wi-Fi solutions in millimeter wave bands, leveraging Quantenna’s advanced 8x8 MIMO capabilities and Starry’s smart antenna RF technology. The integration of Quantenna 802.11ac and 802.11ax (Wi-Fi 6) chipsets in Starry’s base station technology, Starry Beam, provides end users with ultrafast speeds, increased bandwidth capacity, reliable connections and extended range. Starry first launched its pre-standard 5G, point-to-multipoint fixed wireless technology in 2016 in Boston; with Quantenna, Starry will continue to expand its network footprint to cities across the country, including Los Angeles, Washington, DC and New York City. Quantenna QSR10GU and QSR10GU-AX solutions support up to 10Gbps speed, 8x8 MIMO and advanced multi-user MIMO, delivering the maximum capacity within the minimum utilized spectrum, resulting in superior perf

Bombardier-Alstom consortium to supply 153 additional AZUR metro cars for Montréal12.11.2018 13:48Pressemelding

Order valued at approximately $448 million CDN With 60% Canadian content, contract will leverage a network of several hundred suppliers across Québec BERLIN, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Note to editors: To view the photo associated with this press release, please visit the following link: http://www.globenewswire.com/NewsRoom/AttachmentNg/a083fc50-492b-4958-8e12-e4f8f1a596d1 The consortium comprising Bombardier Transportation and Alstom has signed an amendment to the initial acquisition contract of October 2010, concluded with Société de transport de Montréal (STM), for the supply of an additional 153 metro cars (17 nine-car trainsets). These cars will move more riders each day with greater reliability and comfort. The value of this new order is approximately $448 million CDN ($340 million US, 299 million euro). Bombardier's share is valued at $281 million CDN ($213 million US, 188 million euro), and Alstom's share is valued at $167 million CDN ($127 million US, 112 million euro)

Standard Lithium Signs Joint Venture Term Sheet With Global Specialty Chemical Company LANXESS12.11.2018 12:30Pressemelding

VANCOUVER, British Columbia, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLL) (OTC-NASDAQ INTL DESIGNATION: STLHF) (FRA: S5L), announces that it has signed a term sheet (the “Term Sheet”) with global specialty chemical company LANXESS Corporation (“LANXESS”) for a contemplated joint venture in the commercial production of battery grade lithium from brine extracted from the Smackover Formation in South Arkansas. Standard Lithium is working with LANXESS in a phased approach as per terms of a binding memorandum of understanding, to develop commercial opportunities related to the production, marketing and sale of battery grade lithium products extracted from brine produced from the Smackover Formation. Under the proposed terms of the joint venture, LANXESS would contribute lithium extraction rights and grant access to its existing infrastructure to the joint venture, and Standard Lithium would contribute existing rights and leases he

Media Alert: Fifteenth World Robot Olympiad Finals Set in Thailand12.11.2018 11:00Pressemelding

Surprise Rules & Automation Will Challenge Young Competitors to Solve Real Problems at Popular Annual Event SUNNYVALE, Calif. and BILLUND, Denmark, Nov. 12, 2018 (GLOBE NEWSWIRE) -- The World Robot Olympiad™ Association plus joint sponsors LEGO® Education and Juniper Networks (NYSE: JNPR), an industry leader in automated, scalable and secure networks, today announced this year’s global finals are due to take place starting this Friday, November 16, in Chiang Mai, Thailand. Four-hundred and eighty-four teams, comprising over 1,200 individuals from 63 different countries, are due to participate across eight age- and task-based categories. The teams will demonstrate their ability to problem-solve and innovate using LEGO-based robots they have designed, built and programmed themselves. This year’s event has a theme of ‘Food Matters’, around which some of the competitive challenges are based. The challenges are known in advance so the teams can prepare their approach, but they must also dea

Mash Group Plc Reports Interim Unaudited Q3 Financials, ended 30th September 201812.11.2018 10:17Pressemelding

Record revenue for the first nine months of 2018, up 167% from Q1-Q3/17. EBIT grew by 186% to EUR 9.5 million and lending volume grew by 161% for the same period. Revenue growing faster than lending volumes in the third quarter and strong growth expected to continue in Q4 2018, according to CEO Hickson. The first nine months of 2018 showed record growth in revenue, EBIT, lending volume and loan book as Mash continues to execute its growth plan. Strategic Highlights Mash announces launch of EUR 50 million equity issue as well as Europe’s first regulated digital share issue. Mash pay later services were launched in Sweden with partner Verifone. Mash develops partnership with Nets for ecommerce and point of sale, a leading payment services operator in the Nordic market. Operational Highlights The number of new customers grew by 229% Q1-Q3/18 compared to Q1-Q3/17. Registered merchants for Mash’s pay later point of sale solution grew 1054% year to date. The Mash Net Promoter Score reached 8

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom